Mark A. Goldberg

Biography

  Dr. Mark A. Goldberg, M.D., has been an Acting Chief Medical Officer of CANbridge Life Sciences Ltd. since October 20, 2015. Dr. Goldberg served as Executive Vice President of Global Medical and Regulatory Strategy at Synageva BioPharma Corp. until October 2015. Dr. Goldberg has served as an Executive Officer of the Synageva BioPharma. Dr. Goldberg served as Senior Vice President of Product Development, Medical & Regulatory Affairs at Synageva BioPharma Corp. since September 2011 and Senior Vice President of Global Medical and Regulatory Affairs from September 2011 to January 2014 and served as its Senior Vice President of Product Development. Dr. Goldberg joined the Synageva BioPharma from Genzyme Corporation, where Dr. Goldberg served as Senior Vice President of Clinical Development and Global Therapeutic Group Head of Oncology and Personalized Genetic Health from 1996 to July 2011. While at Genzyme, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme, Aldurazyme, Myozyme and Lumizyme. Prior to working at Genzyme, he was a full time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute, where he still holds appointments. He has been a Member of Advisory Board at CANbridge Life Sciences Ltd since September 26, 2013. He has been a Director of GlycoMimetics, Inc. since July 8, 2014. He has been an Independent Director at ImmunoGen, Inc. since November 2011. He has been a Director at Idera Pharmaceuticals, Inc., since January 7, 2014 and Blueprint Medicines Corporation since June 2015. He served as a Director of aTyr Pharma, Inc. since April 2015 until December 11, 2017. He served as a Director of Synageva BioPharma Corp. (alternatively Private Synageva) from October 2008 to December 15, 2011. He has been a Clinical Associate Professor of Medicine at Harvard Medical School since 1996. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Dr. Goldberg plays a central role in developing medical and regulatory strategy and ensuring the successful progress and advancement of pipeline programs. Dr. Goldberg holds A.B. (magna cum laude) from Harvard College and M.D. (cum laude) from Harvard Medical School.

Research Interest

Life Science